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Abstract
The response to viral infection generally includes an activation of the adaptive immune response to produce cytotoxic T cells and neutralizing antibodies. We propose that SARS-CoV-2 activates the innate immune system through
the renin-angiotensin and kallikrein-bradykinin pathways, blocks interferon production and reduces an effective adaptive immune response. This model has therapeutic implications.
Patients suffering from Covid-19, the disease caused by
SARS-CoV-2, have uncontrolled inflammation (Tay et al.
2020). Often in the context of infection, this is thought to
represent cytokine storm with a major contribution from
lymphoid cells. However, there is little evidence of excessive lymphoid activation in the blood of infected individuals; in fact, severe infection is characterized by lymphopenia and patients with severe infection exhibit a high
neutrophil to lymphocyte ratio (Guan et al. 2020). Moreover, while there is an antibody response that develops in
infected individuals, a detectable antibody response can
be achieved without massive lymphoid activation (Quinti
et al. 2020). Here we propose that the systemic inflammation seen in Covid-19 patients results from the activation
of two intersecting systems, the renin-angiotensin system
(RAS) and the kallikrein-bradykinin system (Diamond
2020). These two systems together can serve to promote
inflammation without activating an adaptive immune
response. Moreover, their activation diminishes production of type 1 interferon leading, we propose, to a pathologic condition in Covid-19 patients characterized by systemic inflammation and sustained viral replication.
Both the RAS and the kallikrein-bradykinin system
have long been appreciated for their importance in vascular biology (Gobel et al. 2019). Both also contribute
to immune modulation (Garvin et al. 2020; Seliga et al.
2018). Angiotensin II, a major effector molecular in the
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RAS, is derived from angiotensin I through the action of
angiotensin converting enzyme (ACE) (Donoghue et al.
2000). Angiotensin II has 2 receptors, AT1 and AT2,
that are expressed on a broad range of cells (Clarke et al.
2012). The binding of angiotensin II to AT1 promotes
vasoconstriction but also promotes inflammation, with
activation of NFκB dependent cytokines but not type 1
interferon (Benigni et al. 2010). Engagement of AT2 by
angiotensin II, in contrast, induces vasodilatation and
IL-10 production (Crowley and Rudemiller 2017). Under
inflammatory conditions, AT1 expression is increased,
thereby amplifying an inflammatory program (Crowley and Rudemiller 2017; Koka et al. 2008; Tikellis and
Thomas 2012). Of importance to our understanding of
Covid-19 pathology, angiotensin II can block monocyte
to dendritic cell differentiation impairing the initiation
of an adaptive immune response (Ingersoll et al. 2011)
and can also cause T cell apoptosis (Odaka and Mizuochi
2000), thereby limiting the contribution of the adaptive
immune response and contributing to the lymphopenia
of Covid-19 patients.
ACE2 is a membrane-bound protease that cleaves angiotensin II to produce ang1-7, a peptide which can bind
Mas, a G protein coupled receptor (Gheblawi et al. 2020).
This receptor ligand interaction initiates vasodilatation
and an anti-inflammatory program. Thus, angiotensin II
can be either pro or anti-inflammatory depending on the
relative expression of AT1, AT2 and ACE2 (Crowley and
Rudemiller 2017; Koka et al. 2008; Tikellis and Thomas
2012). A major function of ACE2 is to reduce the amount
of angiotensin II, in addition, angiotensin II and ACE2
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often have contrasting effects. In particular, angiotensin
II facilitates release of HMGB1 from numerous cell types
and ACE2 inhibits its release (Zhou et al. 2018). HMGB1
is a pro-inflammatory cytokine or a chemokine depending on its redox state (Andersson and Tracey 2011). It is
important in myeloid cell activation, but it also affects
hematopoiesis, aborting erythropoiesis and skewing to
myelopoiesis and away from lymphopoiesis (ValdesFerrer et al. 2015). We suggest this molecular pathway,
therefore, may also contribute to the lymphopenia seen
in Covid-19 patients.
ACE is important not only because it converts angiotensin I to angiotensin II, but also because it degrades
bradykinin. Bradykinin arises through the kallikrein
bradykinin pathway (Seliga et al. 2018). It has 2 receptors (Bhoola et al. 1992). BR2 is constitutively expressed
on many cells (Marceau and Regoli 2004). The bradykinin-BR2 interaction leads to vasodilatation and suppresses type 1 interferon production (Seliga et al. 2018).
BR1, which is induced during inflammation, is involved
in amplifying inflammatory pathways. Thus, high ACE
favors vasoconstriction and inflammatory cytokines
by increasing available angiotensin II and decreasing
available bradykinin. Low ACE decreases inflammatory cytokines and permits type 1 interferon production
(Crowley and Rudemiller 2017; Koka et al. 2008; Tikellis
and Thomas 2012; Hadjadj et al. 2020).
These pathways intersect with the SARS-CoV-2 virus,
as ACE2 is the cellular receptor for the spike protein of
the virus (Lan et al. 2020). When ACE2 is engaged by the
virus, ADAM17 (also called TACE) is activated to cleave
ACE2 from the membrane. Soluble ACE2 is less effective at converting pro-inflammatory angiotensin II into
ang1-7 and biases the RAS toward inflammation (Simoes
et al. 2013). The engagement of these pathways helps
explain how severe Covid-19 infection is characterized by
massive inflammation in multiple target organs, a poor
anti-viral response with little production of interferon,
and little participation of the adaptive immune system.
Indeed, it is the interferon pathway that may be most
important in conferring protection against severe disease
as agammaglobulinemic individuals do not appear to be
at increased vulnerability to infection with SARS-CoV-2
(Quinti et al. 2020).
There are three major cell types in this model that
mediate acute severe Covid-19 symptomatology: myeloid
cells, both neutrophils and macrophages, microglia, and
endothelial cells. Macrophages and neutrophils in blood
are clearly activated (Vabret et al. 2020). There was evidence of microglial activation in patients succumbing to
SARS (Xu et al. 2005); the data on microglial activation
in SARS-CoV-2 patients is not yet available. There is evidence for endothelial cell activation (Reichard et al. 2020)
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with reports of massive thrombosis in Covid-19 patients
(Oxley et al. 2020). While the overall data on endothelial
cell activation are indirect (Herman et al. 2020), the case
reports are compelling (Mao et al. 2020; Solomon et al.
2020; Jaunmuktane et al. 2020; Ellul et al. 2020).
There are three major organs to consider in individuals
with severe Covid-19 infection.

Covid‑19 and the lungs
Respiratory transmission appears to be the primary route
of infection in adults as both nasal and lung epithelial
cells express ACE2 (Tay et al. 2020). The lower infection
rate in children may relate, in part, to the lower expression of ACE2 on their nasal epithelium (Patel and Verma
2020). Infection of alveolar epithelial cells by virus leads
to their death through cytopathic effects of the virus, and
consequently to hypoxia. Hypoxia upregulates HIF1α
leading to impaired interferon production but intact
production of proinflammatory cytokines (Wobben
et al. 2013). In the lung, bradykinin causes fibroblasts to
produce chemoattracts for neutrophils (Ehrenfeld et al.
2006). Both angiotensin II and bradykinin increase vascular permeability, leading to extravasation of neutrophils into the lung. As serum from SARS-CoV-2 patients
has been shown to induce netosis (Wang et al. 2020), it
is highly likely that netosis occurs within alveolae further
compromising lung function and leading to acute respiratory distress syndrome in some (Vabret et al. 2020).
Covid‑19 and the brain
The effect of Covid-19 on the central nervous system
has received some attention, but perhaps not enough.
The virus responsible for SARS was found in brain tissue
and the CSF (Xu et al. 2005; Hung et al. 2003). In general, virus may enter the brain by infecting leucocytes
that penetrate a compromised blood brain barrier (BBB),
by infecting brain-microvascular endothelium to enter
the brain, or by direct penetration of nerves or microglia
(Koyuncu et al. 2013). In the case of a virus like SARSCoV-2 which is transmitted by inhalation, the virus most
likely enters through olfactory bulb epithelial cells (Bilinska et al. 2020), and then enters ACE2 expressing microglia and neurons (Xu et al. 2005; Jaunmuktane et al. 2020;
Ellul et al. 2020), although other recent studies suggest
that non-neuronal cell types play a role in the development of anosmic symptoms (Bilinska et al. 2020; Brann
et al. 2020). This direct entry of virus into brain parenchyma might account for the fact that anosmia is often
a presenting symptom of Covid-19 infection. Once brain
cells are infected and there is evidence for infection by
glia by SAR-CoV-2, the RAS can be activated locally to
initiate neuroinflammation. Microglia produce angiotensinogen, the precursor to angiotensin I and neurons
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produce ACE; both cell types express AT1 (Lanz et al.
2010). That the RAS can be important in sustaining neuroinflammation has been seen in Alzheimer’s disease
and in a model of neuropsychiatric SLE (Oliveira et al.
2014; Nestor et al. 2018; Nocito et al. 2020). Moreover,
HMGB1, which is released by activated microglia, potentiates the activation of the N-methyl d-aspartate receptor
(NMDAR) on excitatory neurons (Balosso et al. 2014),
with excessive activation leading to excitotoxic neuron death. The greater the activation of NMDARs, the
greater release of proinflammatory HMGB1 by neurons,
creating a positive feedback loop. Moreover, type 1 interferon induces production of quinolinic acid by microglia
through an indolamine 2,3-dioxygenase (lDO) dependent
pathway (Kwidzinski and Bechmann 2007); quinolinic
acid is an NMDAR agonist. Thus, the amount of interferon that is induced by the SARS-CoV-2 virus may be
inadequate for controlling viral replication but capable of
enhancing an inflammatory environment that facilitates
excitotoxic neuron death. In this model, viral infection in
the brain can generate self-sustaining pathologic neuroinflammation. Indeed, as survivors of severe infection are
followed through the recovery stage it is clear that many
suffer from persistent cognitive impairment which may
represent both neuronal loss and neuronal dysfunction
(Helms et al. 2020).

Covid‑19 and the vasculature
Angiotensin II binds AT1 on endothelial cells and leads
to release of HMGB1 (Zhou et al. 2018; Nair et al. 2015),
chemokines and pro-inflammatory cytokines and to
increased vascular permeability. Of critical importance, activation of AT1 on endothelial cells also leads to
increased expression of tissue factor which is necessary
for thrombosis (Kunieda et al. 2003), a well appreciated
and common morbidity in individuals with Covid-19. The
combination of high expression of tissue factor on activated endothelial cells and activated monocytes favors a
procoagulation state. Many Covid-19 patients also produce anti-phospholipid antibodies which also contribute
to thrombosis (Zhang et al. 2020a).
This model applies to those with severe infection,
many of whom have preexisting conditions, such as
obesity or being elderly, that lead to increased angiotensin II and AT1, or reduced ACE2 (Feraco et al. 2013;
Hajifathalian et al. 2020; Chung et al. 2020). There
appears, in contrast, to be a subset of Covid-19 patients
who have mild symptoms and develop high antibody
titers. We hypothesize that these individuals produce
high levels of type 1 interferon which control the virus
and deviate the B cell response to extrafollicular differentiation of plasma cells leading to high titers of antibody but no memory B cells. Indeed, survivors of SARS
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exhibited a lack of memory B cells (Wec et al. 2020).
We would suggest that these individuals have a RAS
skewed to higher ACE2 and anti-inflammatory pathways, and to pathways that do not inhibit production of
type 1 interferon.
Current and potential therapeutic interventions:
Interferon is likely the most important intervention at
the beginning of the viral infection as it might block viral
replication. It will be less effective in already severe infection characterized by inflammation (Sheahan et al. 2020;
Mueller 2020). Here (Fig. 1), we emphasize the need to
explore interventions that specifically target the RAS or
kallikrein-bradykinin pathway which we hypothesize are
the major contributors to severe inflammation.
Several candidate therapeutics focus on the virus, targeting viral replication (remdesivir), viral entry (Arbidol,
APN01, convalescent plasma, monoclonal antibodies (REGN-COV2), camostat mesylate), or critical viral
proteins (protease inhibitors). Therapies targeting other
viral entry receptors including CD147 (Ulrich and Pillat 2020) and GPR178 (Ulrich and Pillat 2020; Elfiky
2020) are other avenues of investigation. Several promising therapeutics are designed to block viral entry pathways or prevent propagation and spread of the virus in
susceptible organs. These may, like interferon, be useful
early in disease. Other therapies focus on host inflammatory mediators (IFN-α, IFN-β, TZLS-501:IL-6 specific
mAb (monoclonal antibodies), TJM2:GM-CSF-directed
Ab). Some of these strategies and others are reviewed in
(Tay et al. 2020; Tu et al. 2020; Lima et al. 2020). Most
recently, the FDA approved remdesivir for emergency
use authorization (EUA) in COVID-19. At the same time,
the World Health Organization (WHO) discontinued
the hydroxychloroquine and lopinovir/ritonavir arms
of its Solidarity trial (https://www.who.int/news-room/
detail/04-07-2020-who-discontinues-hydroxychloroqu
ine-and-lopinavir-ritonavir-treatment-arms-for-COVID
-19. The only successful therapy to date to dampen host
inflammation is dexamethasone, which affects multiple pathways and cell types. There has been controversy
regarding targeting the RAS. Initially, there was concern
that ACE inhibitors might exacerbate disease, but studies suggest they may, in fact, be of modest benefit (Patel
and Verma 2020; Zhang et al. 2020b). Angiotensin receptor antagonists (losartan and telmisartan; ClinTrials.gov:
NCT04355936) also warrant consideration. Some therapies in development are now also addressing the RAS.
As ACE2 is the main viral entry receptor, ACE2 receptor
antagonists based on peptides from the viral spike protein are being synthesized and tested, in addition to spike
protein-targeted antagonists derived from critical binding regions in the ACE2 receptor (VanPatten et al. 2020).
Therapeutics which target TACE and would inhibit

Diamond et al. Mol Med

(2020) 26:103

Page 4 of 6

Fig. 1 ACE2 is a key enzyme in the RAS, catalyzing the metabolism of Ang II to Ang(1-7) and Ang I to Ang(1-9). ACE2 also mediates degradation
of ACE-catalyzed breakdown products, Des-arg9-Bk (B1R agonist) and Lys-des-arg9-Bk. The net result of ACE2 in these two systems is to
counterbalance ACE/Ang II/AT1R and Bradykinin/Des-arg9-Bk/B1R pathways. Through its cellular binding and entry mechanisms, SARS-CoV-2 is
proposed to result in a reduction of ACE2, leading to elevations in Ang I and II, and leading to AT1R stimulation, and Des-arg9-Bk leading to B1R
stimulation thus exacerbating inflammation, vascular leakage, and pro-fibrotic events. Potential therapeutics include those targeted to angiotensin
and bradykinin system related peptides, in addition to peptides targeting the ACE2-viral spike (S) protein interaction

ACE2 shedding (Haga et al. 2010) have also received
consideration.
As we have hypothesized that some of the inflammation induced in severe, and perhaps even moderate,
Covid-19 is the result of dysregulation of the RAS and
kallikrein-bradykinin pathways, the associated players
serve as potential therapeutic targets (Fig. 1) As mentioned above, ACE inhibitors and AT1 blockers (ARBs)
are approved and safe drugs. These pathways could be
also be targeted with AT2 receptor-directed agonists
(such as Angiotensin(1–9), Mas R agonists-AV0991,
Angiotensin(1–7) (Zemlin et al. 2020; Paz Ocaranza et al.
2020). Bradykinin receptor antagonists are of potential
interest, as bradykinin suppresses interferon production,
enhances inflammation and causes vascular permeability (van de Veerdonk et al. 2020; Roche and Roche 2020).
Therapeutics aimed to address the imbalance in angiotensin and kallikrein products pathway as well as inflammatory mediators such as HMGB1 are promising areas
of future research in Covid-19 (Andersson et al. 2020).
We propose that expedited development of therapeutics
that target immune system modifiers focusing on those
in the RAS and kallikrein/bradykinin pathway offer the
most promising avenues for effective treatment of severe
disease.
The rapid sharing of global research information and
the publication of novel hypotheses regarding both
pathogenesis and therapy have greatly enhanced our
understanding of this virus, and the lessons learned

from ongoing clinical trials will continue to guide future
research and therapeutics development.
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